These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1395 related articles for article (PubMed ID: 32385709)
1. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709 [TBL] [Abstract][Full Text] [Related]
2. Real-world data on treatment outcomes in Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036 [TBL] [Abstract][Full Text] [Related]
3. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754 [TBL] [Abstract][Full Text] [Related]
4. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation. Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616 [TBL] [Abstract][Full Text] [Related]
5. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre. Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049 [TBL] [Abstract][Full Text] [Related]
6. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer. Lee K; Kim D; Yoon S; Lee DH; Kim SW Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716 [TBL] [Abstract][Full Text] [Related]
7. Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer. Lee J; Kim HS; Lee B; Kim HK; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH Cancer; 2020 Jun; 126(11):2704-2712. PubMed ID: 32154925 [TBL] [Abstract][Full Text] [Related]
8. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931 [TBL] [Abstract][Full Text] [Related]
9. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M. Zhao S; Li X; Zhao C; Jiang T; Jia Y; Shi J; He Y; Li J; Zhou F; Gao G; Li W; Chen X; Su C; Ren S; Zhou C Lung Cancer; 2019 Feb; 128():33-39. PubMed ID: 30642450 [TBL] [Abstract][Full Text] [Related]
10. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation. Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670 [TBL] [Abstract][Full Text] [Related]
11. Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer. Lin YT; Tsai TH; Wu SG; Liu YN; Yu CJ; Shih JY Lung Cancer; 2020 Jul; 145():1-9. PubMed ID: 32387812 [TBL] [Abstract][Full Text] [Related]
12. Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M. Wang LS; Chen SQ; Zhong X; Jiao XD; Liu K; Qin BD; Wu Y; Ling Y; Duan XP; Zang YS Anticancer Drugs; 2023 Nov; 34(10):1146-1150. PubMed ID: 36728908 [TBL] [Abstract][Full Text] [Related]
13. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status. Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T; Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616 [TBL] [Abstract][Full Text] [Related]
14. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib. Hochmair MJ; Buder A; Schwab S; Burghuber OC; Prosch H; Hilbe W; Cseh A; Fritz R; Filipits M Target Oncol; 2019 Feb; 14(1):75-83. PubMed ID: 30539501 [TBL] [Abstract][Full Text] [Related]
15. Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer. Ichihara E; Hotta K; Ninomiya K; Kubo T; Ohashi K; Rai K; Tanaka H; Tabata M; Maeda Y; Kiura K Lung Cancer; 2019 Jun; 132():54-58. PubMed ID: 31097094 [TBL] [Abstract][Full Text] [Related]
16. Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib. Kuo CS; Huang CH; Liu CY; Pavlidis S; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT Target Oncol; 2019 Aug; 14(4):433-440. PubMed ID: 31346928 [TBL] [Abstract][Full Text] [Related]
17. Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation. Wang S; Yan B; Zhang Y; Xu J; Qiao R; Dong Y; Zhang B; Zhao Y; Zhang L; Qian J; Lu J; Zhao R; Han B Int J Cancer; 2019 Jun; 144(11):2880-2886. PubMed ID: 30474188 [TBL] [Abstract][Full Text] [Related]
18. Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib. Minari R; Leonetti A; Gnetti L; Zielli T; Ventura L; Bottarelli L; Lagrasta C; La Monica S; Petronini PG; Alfieri R; Tiseo M Anticancer Drugs; 2021 Aug; 32(7):758-762. PubMed ID: 33675607 [TBL] [Abstract][Full Text] [Related]
19. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. Auliac JB; Pérol M; Planchard D; Monnet I; Wislez M; Doubre H; Guisier F; Pichon E; Greillier L; Mastroianni B; Decroisette C; Schott R; Le Moulec S; Arrondeau J; Cortot AB; Gerinière L; Renault A; Daniel C; Falchero L; Chouaid C Lung Cancer; 2019 Jan; 127():96-102. PubMed ID: 30642559 [TBL] [Abstract][Full Text] [Related]
20. Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI. Chiang CL; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH Target Oncol; 2020 Aug; 15(4):503-512. PubMed ID: 32696212 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]